|
Cardiff Oncology Inc (NASDAQ: CRDF) |
|
Cardiff Oncology Inc
CRDF's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Cardiff Oncology Inc 's sales fell
by -90.36 % in the first quarter of 2025 from the same quarter a year ago.
Biotechnology & Pharmaceuticals industry recorded
growth of revenues by 11.44 %
Cardiff Oncology Inc net loss increased from $-10 millions, to $-13 millions in first quarter of 2025,
• More on CRDF's Growth
|
|
Cardiff Oncology Inc realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 32.67 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 406.45.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 5.84.
• More on CRDF's Valuation
|
|
|
|
|
Cardiff Oncology Inc realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 32.67 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 406.45.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 5.84.
Cardiff Oncology Inc Price to Book Ratio is at 2.51 higher than Industry Avg. of -61774.74, and higher than S&P 500 Avg. of 0.01
• More on CRDF's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com